Pfizer Inc. has surpassed quarterly profit expectations and unveiled plans for an additional $2.5 billion in cost reductions, as steady demand for its non-Covid portfolio helped offset a continued decline in pandemic-era revenue.
The drugmaker reported stronger-than-forecast earnings driven in part by robust sales of its blood thinner Eliquis, signaling that the company’s core commercial business is stabilizing after years of turbulence tied to the fading Covid-19 market.
On the strength of those results, Pfizer raised its 2026 guidance, a move that underscores management’s confidence in the company’s ability to weather the sharp drop-off in Covid vaccine and treatment sales that once fueled record revenue.
The newly announced savings build on an already sweeping efficiency drive. The company has spent the past two years overhauling its cost structure, and the latest target adds to a multibillion-dollar program aimed at streamlining operations and protecting margins.
This development comes as Pfizer works to reposition itself around long-term growth franchises, including oncology and other specialty treatments, while reducing its reliance on the volatile Covid product line that has swung dramatically since 2021.
The company had earlier this year extended its cost-cutting campaign after beating first-quarter forecasts, indicating that the drive to trim expenses has been a consistent theme throughout the year.
Eliquis, developed in partnership with Bristol Myers Squibb, remains one of Pfizer’s most important revenue contributors and helped anchor the quarter amid broader portfolio pressures.
Despite these gains, the company continues to face headwinds, including the anticipated loss of patent exclusivity on several key products in the coming years and ongoing uncertainty around U.S. trade and tariff policy affecting the pharmaceutical sector.
The raised outlook and expanded savings plan are expected to reassure investors who have watched Pfizer’s shares trade well below their pandemic-era peaks. The company is betting that disciplined spending combined with a refreshed drug pipeline will restore steadier growth.
Pfizer is anticipated to provide further detail on its cost-reduction timeline and pipeline milestones in the months ahead, as it continues its multi-year effort to transition beyond the Covid era.